An observational study in Primary Ciliary Dyskinesia (PCD), sponsored by Izmir Democracy University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Izmir Democracy University · Observational
The prevalence and causes of malnutrition and sarcopenia in children and adolescents with Primary ciliary dyskinesia (PCD) have not been sufficiently elucidated. The aim of this study is to investigate the prevalence of malnutrition and sarcopenia in children and adolescents with PCD.
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder characterized by abnormal ciliary motility and impaired mucociliary clearance. It develops as a result of mutations in genes responsible for ciliary movement. Structural or functional abnormalities of cilia lead to chronic upper and lower respiratory tract infections, fertility problems, and organ laterality defects. The prevalence of PCD ranges from 1 in 2,000 to 1 in 40,000, varying among different ethnic groups. The disease begins to negatively affect lung function from the preschool period onward. In children with PCD, respiratory function is generally characterized by mild to moderate airway obstruction. As the disease progresses, the severity of airway obstruction increases. Therefore, regular monitoring of pulmonary function is of great importance in the management of PCD. The prevalence and causes of malnutrition and sarcopenia in children and adolescents with PCD have not been sufficiently elucidated. The aim of this study is to investigate the prevalence of malnutrition and sarcopenia in children and adolescents with PCD.
79 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.
This study's planned enrollment of 15 is below the median of 130 across 55 observational studies indexed under Ciliary Motility Disorders.
Browse Ciliary Motility Disorders studies →Izmir Democracy University is the lead sponsor of 78 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will include children and adolescents aged 6-18 years with Primary Ciliary Dyskinesia (PCD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for children and adolescents with PCD
Inclusion criteria for healthy children and adolescents:
1. Voluntary participation in the study
Exclusion Criteria:
Exclusion criteria for children and adolescents with PCD:
The study will include children and adolescents with PCD aged 6 to 18 (n=15).
Other: Physical assessments of individuals
Participants will be evaluated in terms of nutritional status, anthropometric measurements (waist circumference, hip circumference, waist-to-height ratio, skinfold measurements) and body composition, pulmonary functions, anaerobic capacity, muscle strength.
Handgrip Muscle Strength in Participants
Bilateral grip strength in children and adolescents with PCD will be measured in kgF using a hand dynamometer.
Time frame: From enrollment to the end of treatment at 1 year
Malnutrition risk score in Participants
The Nutritional Status and Growth Risk Screening Tool will be used to assess the risk of growth failure. The total score on this scale ranges from 0 to 5; a score of 0 indicates a low risk of malnutrition, a score of 1-3 indicates a moderate risk of malnutrition, and a score of 4-5 indicates a high risk of malnutrition.
Time frame: From enrollment to the end of treatment at 1 year
Body Weight
Body weight in children and adolescents with PCD will be measured using a pediatric scale.
Time frame: From enrollment to the end of treatment at 1 year
Height
In children and adolescents with PCD, height will be measured using a stadiometer.
Time frame: From enrollment to the end of treatment at 1 year
Body Mass Index
For children and adolescents with PCD, the body mass index will be calculated by dividing body weight by the square of height in meters.
Time frame: From enrollment to the end of treatment at 1 year
Waist circumference
Waist circumference in children and adolescents with PCD will be measured using a tape measure
Time frame: From enrollment to the end of treatment at 1 year
Hip circumference
Hip circumference in children and adolescents with PCD will be measured using a tape measure
Time frame: From enrollment to the end of treatment at 1 year
Waist-to-hip ratio
In children and adolescents with PCD, the waist-to-hip ratio will be calculated by dividing the waist circumference by the hip circumference.
Time frame: From enrollment to the end of treatment at 1 year
Waist-to-Height ratio
In children and adolescents with PCD, the waist-to-height ratio will be calculated by dividing the waist circumference by the height.
Time frame: From enrollment to the end of treatment at 1 year
Upper-middle arm circumference
In children and adolescents with PCD, upper arm circumference will be measured using a non-stretchable tape measure, without tightening it or leaving any slack.
Time frame: From enrollment to the end of treatment at 1 year
Triceps skinfold thickness
In children and adolescents with PCD, triceps skinfold thickness will be measured using a skinfold caliper.
Time frame: From enrollment to the end of treatment at 1 year
Body fat percentage
Body fat percentage in children and adolescents with PCD will be measured using bioelectrical impedance analysis.
Time frame: From enrollment to the end of treatment at 1 year
Height by Age
The percentile values for height by age in children and adolescents with PCD will be determined using data from the CDC's website.
Time frame: From enrollment to the end of treatment at 1 year
Weight by Height
The percentile values for Weight by Height in children and adolescents with PCD will be determined using data from the CDC's website.
Time frame: From enrollment to the end of treatment at 1 year
Weight by Age
The percentile values for Weight by Age in children and adolescents with PCD will be determined using data from the CDC's website.
Time frame: From enrollment to the end of treatment at 1 year
Body Mass Index by Age
Body Mass Index (BMI) is an anthropometric index calculated by dividing body weight in kilograms by the square of height in meters. Body Mass Index by Age (BMI-for-Age) is the body mass index (BMI) adjusted for age and sex and interpreted using age- and sex-specific growth reference charts.The percentile values for Body Mass Index by Age in children and adolescents with PCD will be determined using data from the CDC's website.
Time frame: From enrollment to the end of treatment at 1 year
Forced Expiratory Volume at One Second
Forced Expiratory Volume at One Second is the volume of air that an individual can forcibly exhale during the first second of a maximal forced expiration following a full inspiration. It is typically expressed in liters or as a percentage of the predicted value (% predicted).
Time frame: From enrollment to the end of treatment at 1 year
Forced Vital Capacity
Forced Vital Capacity is the total volume of air that an individual can forcibly exhale after taking a maximal inspiration. It is typically expressed in liters (L) or as a percentage of the predicted value (% predicted).
Time frame: From enrollment to the end of treatment at 1 year
Forced Expiratory Volume at One Secondto Forced Vital Capacity Ratio
Forced Expiratory Volume at One Second to Forced Vital Capacity Ratio is the proportion of the forced vital capacity that is exhaled during the first second of a forced expiration following a maximal inspiration. It is expressed as a percentage.
Time frame: From enrollment to the end of treatment at 1 year
Peak Expiratory Flow
Peak Expiratory Flow is the maximum expiratory flow rate achieved during a forced expiration following a maximal inspiration. It is typically expressed in liters per minute.
Time frame: From enrollment to the end of treatment at 1 year
Forced Expiratory Flow at 25-75% of Forced Vital Capacity
Forced Expiratory Flow at 25-75% of Forced Vital Capacity is the average forced expiratory flow measured during the middle 50% of the forced vital capacity maneuver, specifically between 25% and 75% of the exhaled volume. It is typically expressed in liters per second.
Time frame: From enrollment to the end of treatment at 1 year
Plan to share: No
Start is estimated for Aug 2026; primary completion for Jul 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Izmir Democracy University